Uwe Wagner
Papers
1
Total Citations
40
H-Index
1
About
Uwe Wagner is a leading clinical researcher in gynecologic oncology, with a primary focus on ovarian cancer biomarkers and targeted therapy strategies. His most cited work centers on homologous recombination deficiency (HRD) as a critical diagnostic tool for ovarian carcinoma. In a landmark 2022 study analyzing 514 real-world tumor samples, Wagner demonstrated how next-generation sequencing of DNA libraries—including BRCA1/BRCA2 and over 26,000 single-nucleotide variants—can effectively evaluate HRD status. This research has been cited 40 times, underscoring its importance in defining personalized treatment approaches for patients. Wagner’s contributions bridge the gap between genomic discovery and clinical application, helping to identify which ovarian cancer patients may benefit from PARP inhibitors and other targeted therapies. His work has significantly advanced the precision oncology landscape, providing a robust framework for integrating HRD testing into routine diagnostic workflows. For students and researchers, Wagner exemplifies how translational research can directly impact patient care, turning complex genomic data into actionable clinical decisions that improve outcomes in one of the most challenging malignancies.
Research Focus
Key Achievements
Top Papers
- 1